Biovica: Committed to developing and commercializing novel blood-based biomarker assays.
Biovica is a Swedish biotech company founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.
Clinical validation: The DiviTum® TKa test was selected for support and funding by the European Commission Horizon 2020 phase 2 program.